Morocco

2020 Edition

Preface

Somewhat of a bastion of openness, predictability, and stability in a region often mired with turmoil, volatility, and economic nationalism, Morocco is increasingly attracting the attention of international investors across a range of industries. Nowhere is this more apparent than in the life sciences, where companies are taking note of the country’s strong business fundamentals, solid financial system, international-standard manufacturing, skilled human capital, and reputable legal framework.

Though not an enormous domestic pharma market at USD 1.6 billion, Morocco’s position at the crossroads between Europe and Africa is becoming ever more attracting as a base for international firms looking to locate pan-North African functionalities. Recent years have also seen big ticket investments in Moroccan production sites from the likes of Pfizer, Mylan, Sun Pharma, and Cipla. Moreover, domestic Moroccan companies are rapidly internationalising, bringing their products to markets across Africa and tying up partnerships with European counterparts.

The Moroccan authorities are also helping create a progressively more pharma-friendly environment with a push to broaden access to healthcare and harmonise regulatory, pricing, and reimbursement processes leading to shorter market access timeframes. Additionally, there have been no signs of the preference for locally manufactured drugs in public tenders seen in some other North African countries.

Challenges are nevertheless rife, as in all emerging markets, including serious distortions in access to healthcare among the Moroccan population. On a company level, it has become very difficult for generics firms to tun a profit in what is an extremely price-conscious market. New strategies and business models are, however, emerging, and the market is bracing itself for an incoming wave of consolidation.

Other topics covered in this comprehensive new report include oncology, women’s and children’s health, rare diseases, clinical trials, and much more.

Read the Full Version
Featured Content
Cover Story
Standing Firm

Valued by Fitch at a trifling USD 1.6 billion, the Moroccan pharma sector can be considered only a middling-size market by regional standards, and much less when set against a global backdrop. Yet the MENA’s 10th largest economy by GDP very much manages to hold its ground when it comes to attracting overseas investment into the life science sector courtesy of a well-honed reputation for openness, predictability and stability in a region far more commonly associated with turmoil, volatility and bouts of economic nationalism.

Facts & Figures
Interviews
Articles

Thanks for reading!

The Digital Version of the Healthcare & Life Sciences Review: Morocco is available and optimized for desktop browsers.

Visit our website with your computer or download the pdf report

Read the Full Version

2020. Healthcare & Life Sciences Review was produced by Pharmaboardroom.

Copyright: All rights reserved. No part of this publication maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors. All the images belongs to its respective authors.

Report Director: Crystelle Coury
Senior Editor: Patrick Burton, Louis Haynes
Publisher: Frederic Boucheseiche
Graphic Designer: Miriam León

PharmaBoardroom

Contact us

+44 20 7867 3717 info@pharmaboardroom.com

For media inquiries, please contact: media@pharmaboardroom.com

Address

PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT

Subscribe